University of the Frontier

www.ufro.cl
Temuco, Chile

University of the Frontier or UFRO is a university in Temuco Chile. It is a derivative university and part of the Chilean Traditional Universities. UFRO boasts a student body with a variety of abilities and from a variety of backgrounds, many of them are Mapuche descent. Wikipedia.


Time filter

Source Type

News Article | July 24, 2017
Site: globenewswire.com

Hyden, KY, July 24, 2017 (GLOBE NEWSWIRE) -- Frontier Nursing University (FNU) has been awarded the Nursing Workforce Diversity grant from the Health Resources and Services Administration (HRSA). The grant totals $1,998,000 in funding in support of a four-year project that will be led by FNU with assistance from several key partner organizations. The goal of the Nursing Workforce Diversity program is to increase access to high quality, culturally-aligned advanced practice nurses and midwives that reflect the diversity of the communities in which they serve. The grant, which provides $499,500 per year, supports a proposed project in which FNU will implement a comprehensive systems approach to implementing five evidence-based strategies to support disadvantaged advanced practice nursing students from recruitment through graduation. The social determinants of education will be used as a framework to assess student needs and guide activities throughout the course of the project. The overall aim of the program is to increase the recruitment, enrollment, retention, and graduation of students from disadvantaged backgrounds. Through education and training in Frontier Nursing University’s advanced nursing and midwifery programs, these students will be prepared to provide advanced practice nursing and midwifery health care services across the U.S. Findings from an American Association of Colleges of Nursing policy brief (2016) found that racial and ethnic minority groups accounted for 37% of the country’s population, yet minority nurses represent only 19% of the total registered nurse workforce (National Council of State Boards of Nursing Survey, 2013).  As minority population growth rises, so does the likelihood of these populations experiencing greater health disparities such as increased rates of maternal morbidity and mortality related to childbirth, infant mortality, chronic diseases, and shorter life spans compared to the majority of Americans. There is growing evidence that greater racial diversity in the health care workforce is an important intervention to reduce racial health disparities. “We are extremely proud and excited to receive this grant and to be a part of such an important project,” said FNU president Dr. Susan E. Stone. “We are deeply committed to the goals of the NWD program and helping to overcome barriers that hinder the success of our underrepresented students, from recruitment through graduation.” The project’s primary objectives are: 1) to achieve minimum of 30 percent minority student enrollment by June 2021, the end of the project period; 2) to increase the racial and ethnic minority retention rate and 3) to graduate an average of 100 new nurse-midwives and nurse practitioners representing racial and ethnic minorities underrepresented in nursing each year of the project period. Grant funding will support personnel, consultants, and diversity training for faculty and staff.  Retention activities, including mentor programs and writing support will also be funded.  FNU students will also benefit from substantial scholarship support and professional development opportunities.  To achieve the goals of the program, FNU will formally partner with the American Association of Colleges of Nursing (AACN), the American College of Nurse-Midwives, Midwives of Color Committee (ACNM-MOCC), the National Black Nurses Association (NBNA) and Mona Wicks, a multicultural sensitivity and diversity training expert consultant. View the grant announcement on the Frontier Nursing University website. The mission of FNU is to educate nurses to become competent, entrepreneurial, ethical and compassionate nurse-midwives and nurse practitioners who are leaders in the primary care of women and families with an emphasis on underserved and rural populations. FNU offers graduate Nurse-Midwifery and Nurse-Practitioner distance education programs that can be pursued full- or part-time with the student’s home community serving as the classroom. Degrees and options offered include Doctor of Nursing Practice (DNP), Master of Science in Nursing (MSN) or Post-Graduate Certificates. To learn more about FNU and the programs and degrees offered, please visit Frontier.edu.


Grant
Agency: European Commission | Branch: FP7 | Program: CPCSA | Phase: INFRA-2010-1.2.3 | Award Amount: 2.76M | Year: 2010

The GISELA objective is to guarantee the long-term sustainability of the European Latin American e-Infrastructure and thus ensure the continuity and enhancement of the Virtual Research Communities (VRC) using it. The project will focus on:\n\tImplementing the Latin American Grid Initiative (LGI) sustainability model rooted on National Grid Initiatives (NGI) or Equivalent Domestic Grid Structures (EDGS), in association with CLARA and collaborating with EGI;\n\tProviding VRCs with the e-Infrastructure and Application-related Services required to improve the effectiveness of their research, addressing both:\no\tCurrent EELA-2 small User Communities;\no\tLarger VRCs through Specialised Support Centres (SSCs).\nThe GISELA mission is twofold:\n- Ensure the sustainability of the EU-LA e-Infrastructure\nThe sustainability of the EU part of the e-Infrastructure being cared of by EGI, GISELA will concentrate on its LA component. The tasks, at each level of the e-Infrastructure are:\n\tInstitution: Get all Services fully operational in the Resource Centre (RC);\n\tCountry: Implement all Grid Operation Centre (GOC) Services;\n\tContinent: Implement all Grid & Network Support Centres (GSC, NSC) Services;\n\tSupport a catchall GOC.\n- Support Virtual Research Communities\nThe support will encompass:\n\tUser Support:\no\tProvide access to the EU-LA Infrastructure to VOs represented in GISELA (HEP, Life Sciences, Earth Sciences, etc.);\no\tPublicise and support the GISELA e-Infrastructure and Application Services;\no\tCollaborate with VRCs or SSCs to the development of integrated services (e.g. gateways).\n\tTraining & Dissemination activities\no\tOrganisation of tutorials for single users and VRCs;\no\tCoordinate dissemination actions, workshops, Conferences;\no\tProduce dissemination material.\nGrid Services for VRCs will be provided by CLARA on the basis of a business plan using a Life Cycle Product Management (LCPM) approach.


Patent
University of the Frontier, University of Chile, Federal University of São Paulo and Laboratorios Andromaco | Date: 2013-01-30

The present invention is directed to an active agent with contraceptive properties. Said active agent corresponds to a molecular fraction of the venom from the spider Latrodectus mirabilis. The active agent is a peptide with a sequence according to SEQ ID NO 1 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. In a preferred embodiment, the active agent with contraceptive properties is a peptide with 10 to 30 amino acids, preferably 20 amino acids. Said embodiment is exemplified by the sequence identified as SEQ ID NO 2 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. Furthermore, a method to obtain the contraceptive peptide is disclosed, said method comprising cloning the nucleotide sequence in a microorganism. A pharmaceutical contraceptive composition comprising at least one peptide according to the abovementioned description and one or more pharmaceutically acceptable vehicles is also described. And finally, the use of the peptide to prepare a pharmacological composition useful as a contraceptive agent, as a spermicide, is disclosed.


The present invention is directed to an active agent with contraceptive properties. Said active agent corresponds to a molecular fraction of the venom from the spider Latrodectus mirabilis. The active agent is a peptide with a sequence according to SEQ ID NO 1 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. In a preferred embodiment, the active agent with contraceptive properties is a peptide with 10 to 30 amino acids, preferably 20 amino acids. Said embodiment is exemplified by the sequence identified as SEQ ID NO 2 or sequences that are at least 85% similar, obtained by chemical synthesis or through recombinant DNA technologies. Furthermore, a method to obtain the contraceptive peptide is disclosed, said method comprising cloning the nucleotide sequence in a microorganism. A pharmaceutical contraceptive composition comprising at least one peptide according to the abovementioned description and one or more pharmaceutically acceptable vehicles is also described. And finally, the use of the peptide to prepare a pharmacological composition useful as a contraceptive agent, as a spermicide, is disclosed.


Seron P.,University of the Frontier
The Cochrane database of systematic reviews | Year: 2014

When two or more cardiovascular risk factors occur in one individual, they may interact in a multiplicative way promoting cardiovascular disease. Exercise has proven to be effective in controlling individual risk factors but its effect on overall cardiovascular risk remains uncertain. To assess the effects of exercise training in people with increased cardiovascular risk but without a concurrent cardiovascular disease on general cardiovascular mortality, incidence of cardiovascular events, and total cardiovascular risk. A search was conducted in CENTRAL (The Cochrane Library 2013, Issue 10 of 12), Ovid MEDLINE (1946 to week 2 November 2013), EMBASE Classic + EMBASE via Ovid (1947 to Week 47 2013), CINAHL Plus with Full Text via EBSCO (to November 2013), Science Citation Index Expanded (SCI-EXPANDED) (1970 to 22 November 2013), and Conference Proceedings Citation Index - Science (CPCI-S) (1990 to 22 November 2013) on Web of Science (Thomson Reuters). We did not apply any date or language restrictions. Randomized clinical trials comparing aerobic or resistance exercise training versus no exercise or any standard approach that does not include exercise. Participants had to be 18 years of age or older with an average 10-year Framingham risk score of 10% for cardiovascular disease over 10 years, or with two or more cardiovascular risk factors, and no history of cardiovascular disease. The selection of studies and subsequent data collection process were conducted by two independent authors. Disagreements were solved by consensus. The results were reported descriptively. It was not possible to conduct a meta-analysis because of the high heterogeneity and high risk of bias in the included studies. A total of four studies were included that involved 823 participants, 412 in the exercise group and 411 in the control group. Follow-up of participants ranged from 16 weeks to 6 months. Overall, the included studies had a high risk of selection, detection, and attrition bias. Meta-analysis was not possible because the interventions (setting, type and intensity of exercise) and outcome measurements were not comparable, and the risk of bias in the identified studies was high. No study assessed cardiovascular or all-cause mortality or cardiovascular events as individual outcomes. One or more of the studies reported on total cardiovascular risk, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, blood pressure, body mass index, exercise capacity, and health-related quality of life but the available evidence was not sufficient to determine the effectiveness of exercise. Adverse events and smoking cessation were not assessed in the included studies. Evidence to date is entirely limited to small studies with regard to sample size, short-term follow-up, and high risk of methodological bias, which makes it difficult to derive any conclusions on the efficacy or safety of aerobic or resistance exercise on groups with increased cardiovascular risk or in individuals with two or more coexisting risk factors. Further randomized clinical trials assessing controlled exercise programmes on total cardiovascular risk in individuals are warranted.


Patent
National University of Cordoba and University of the Frontier | Date: 2012-04-19

A piece of scientific/technological equipment is presented for the generation of a convergent photon beam for radiotherapy or other applications. This equipment consists of adequately modifying the trajectory of an electron beam from a linear accelerator (LINAC) by applying magnetic and/or electric fields. These electrons perpendicularly impact the surface of a curved material that has a particular curvature ratio (anode), thus generating X-rays. The interaction of the electrons with the atoms of the anodes material generate X-rays with a non-isotropic angular-spatial distribution, with a greater concentration in the focal direction, which is defined by the geometry of the anode. A curved collimator with an adequate curvature ratio is attached to the back of the anode. The collimator is made up of an array of a great number of small holes that point toward the focal point. This device transmits X-rays solely in the focal direction. The Summary Figure presents a typical configuration of the invention that has been presented.


This invention relates to a fungicidal composition for controlling phytopathogenic diseases, comprising a mixture of volatile compounds: 14-17% v/v ethanol, 28-33% v/v 3-methylbutanol, 18-21% v/v isobutyl acetate, 17-20% v/v isoamyl acetate, and 13-16% v/v alpha-bisabolol, relative to the total volume of the composition. The invention also relates to the use of the fungicidal composition in order to inhibit the growth of the pathogenic fungus Botrytis cinerea.


Patent
University of the Frontier and National University of Cordoba | Date: 2014-03-26

A piece of scientific/technological equipment is presented for the generation of a convergent photon beam for radiotherapy or other applications. This equipment consists of adequately modifying the trajectory of an electron beam from a linear accelerator (LINAC) by applying magnetic and/or electric fields. These electrons perpendicularly impact the surface of a curved material that has a particular curvature ratio (anode), thus generating X-rays. The interactions of the electrons with the atoms of the anodes material generate X-rays with a non-isotropic angular-spatial distribution, with a greater concentration in the focal direction, which is defined by the geometry of the anode. A curved collimator with an adequate curvature ratio is attached to the back of the anode. The collimator is made up of an array of a great number of small holes that point toward the focal point. This device transmits X-rays solely in the focal direction. The Summary Figure presents a typical configuration of the invention that has been presented.


The present invention discloses a method for cryopreservation of human spermatozoa: the method comprises providing spermatozoa free from seminal liquid; mixing the spermatozoa with vitrification medium, wherein the main cryoprotectant agent is 0.1-0.3 M sucrose; placing the sample inside straws and rapidly freezing them; refrigerating the straws with no need of liquid N_(2); and devitrifying the sample in a medium of the present invention. The present invention furthermore discloses a portable kit that makes easy to implement the method, said kit comprising vitrification and devitrification solutions in the volumes required to develop the method and the physical support to carry out the same, i.e. the straws. The use of this kit is also disclosed for the treatment of disorders related to reproductive failures.


Patent
University of the Frontier and Knop Laboratorios Ltda | Date: 2013-07-10

The invention is referred to a new dentifrice composition with anticariogenic properties, which has as active anticariogenic ingredients a combination of propolis, methylparaben and propylparaben. From these 3 components, propolis is the major component, which is reinforced in its activity for a smaller amount of methylparaben and propylparaben obtaining a composition with a high anticariogenic composition without side effects. These active ingredients are present in the following percentages in relation to the total weight of the dentifrice composition:2 a 10 % of propolis;0,01 a 0,30% of methylparaben0,01 a 0,15% of propylparaben The dentifrice composition also includes a fluorinated compound and other auxiliary components usually used for formulation such as abrasives, moisturizing, foaming agents, thickeners, sweeteners, flavorants and demineralized water.

Loading University of the Frontier collaborators
Loading University of the Frontier collaborators